Hugh H. Tilson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hugh H. Tilson has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Alan Moore
Novartis Pharma AG, Basel, Switzerland
1 shared publication - Barbara Rauer
Novartis Pharma AG, Basel, Switzerland
1 shared publication - Beth L. Nordstrom
Evidera, Waltham, USA
1 shared publication Brian Edwards
Medical Services, PAREXEL International Ltd., Uxbridge, Middlesex, UK
1 shared publication- Dennis Kim
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
1 shared publication - Dorina Bischof
Novartis Pharma AG, Basel, Switzerland
1 shared publication
Latest Publications
- 1 November 2015
- Published by Wolters Kluwer Health in Journal of Public Health Management & Practice
- Vol. 21 (Supplement) , S173-S174
When We Have Data We Can Count on, Everyone WINS
- 1 November 2015
- Published by Wolters Kluwer Health in Journal of Public Health Management & Practice
- Vol. 21 (Supplement) , S173-S174
When We Have Data We Can Count on, Everyone WINS
- Open Access
- 1 November 2015
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 4 (6) , 546-554
Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: An observational study using the US Department of Defense administrative claims database
- 1 November 2015
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 4 (6) , 546-554
Open AccessMortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: An observational study using the US Department of Defense administrative claims database
- Open Access
- 10 September 2013
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 8 (1) , 139
Methodological challenges in monitoring new treatments for rare diseases: lessons from the cryopyrin-associated periodic syndrome registry
Background: The Cryopyrin-Associated Periodic Syndromes (CAPS) are a group of rare hereditary autoinflammatory diseases and encompass Familial Cold Autoinflammatory Syndrome (FCAS), Muckle-Wells Syndrome (MWS), and Neonatal Onset Multisystem Inflammatory Disease (NOMID). Canakinumab is a monoclonal antibody directed against IL-1 beta and approved for CAPS patients but requires post-approval monitoring due to low and short exposures during the licensing process. Creative approaches to observational methodology are needed, harnessing novel registry strategies to ensure Health Care Provider reporting and patient monitoring. Methods: A web-based registry was set up to collect information on long-term safety and effectiveness of canakinumab for CAPS. Results: Starting in November 2009, this registry enrolled 241 patients in 43 centers and 13 countries by December 31, 2012. One-third of the enrolled population was aged < 18; the overall population is evenly divided by gender. Enrolment is ongoing for children. Conclusions: Innovative therapies in orphan diseases require post-approval structures to enable in depth understanding of safety and natural history of disease. The rarity and distribution of such diseases and unpredictability of treatment require innovative methods for enrolment and follow-up. Broad international practice-based recruitment and web-based data collection are practical.
- 10 September 2013
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 8 (1) , 139
Open AccessMethodological challenges in monitoring new treatments for rare diseases: lessons from the cryopyrin-associated periodic syndrome registry
Background: The Cryopyrin-Associated Periodic Syndromes (CAPS) are a group of rare hereditary autoinflammatory diseases and encompass Familial Cold Autoinflammatory Syndrome (FCAS), Muckle-Wells Syndrome (MWS), and Neonatal Onset Multisystem Inflammatory Disease (NOMID). Canakinumab is a monoclonal antibody directed against IL-1 beta and approved for CAPS patients but requires post-approval monitoring due to low and short exposures during the licensing process. Creative approaches to observational methodology are needed, harnessing novel registry strategies to ensure Health Care Provider reporting and patient monitoring. Methods: A web-based registry was set up to collect information on long-term safety and effectiveness of canakinumab for CAPS. Results: Starting in November 2009, this registry enrolled 241 patients in 43 centers and 13 countries by December 31, 2012. One-third of the enrolled population was aged < 18; the overall population is evenly divided by gender. Enrolment is ongoing for children. Conclusions: Innovative therapies in orphan diseases require post-approval structures to enable in depth understanding of safety and natural history of disease. The rarity and distribution of such diseases and unpredictability of treatment require innovative methods for enrolment and follow-up. Broad international practice-based recruitment and web-based data collection are practical.
- 31 January 2013
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 44 (1) , S151-S155
Using Registries to Monitor HIV Pre-Exposure Prophylaxis Safety in Clinical Settings
- 31 January 2013
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 44 (1) , S151-S155
Using Registries to Monitor HIV Pre-Exposure Prophylaxis Safety in Clinical Settings
- 1 November 2009
- Published by Wolters Kluwer Health in Journal of Public Health Management & Practice
- Vol. 15 (6) , S16-S17
Wanted
- 1 November 2009
- Published by Wolters Kluwer Health in Journal of Public Health Management & Practice
- Vol. 15 (6) , S16-S17
Wanted
- 26 September 2005
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 15 (3) , 193-198
Defining the competencies of those conducting pharmacovigilance
Purpose: The absence of agreed competencies in pharmacovigilance and patient risk management is a key factor hindering the development of training and a curriculum in these interrelated disciplines. If competencies were to be developed, they could be tailored to the different roles and responsibilities of the various staff involved.Proposal: We describe a simple theoretical model of functional and behavioural competencies that is based on an organisation with three levels of staff: evidence collectors and gatherers, evidence processors and distillers, and decision makers.Conclusions: To stimulate discussion about how to enhance the progress already being made in pharmacovigilance and patient risk management, we have proposed functional and behavioural competencies for pharmacovigilance as a way of identifying and measuring scientific and personal skills pertinent to pharmacovigilance. Competencies should, we believe, be agreed and adopted by all those seeking to improve pharmacovigilance. We invite discussion of these proposals. Copyright © 2005 John Wiley & Sons, Ltd.
- 26 September 2005
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 15 (3) , 193-198
Defining the competencies of those conducting pharmacovigilance
Purpose: The absence of agreed competencies in pharmacovigilance and patient risk management is a key factor hindering the development of training and a curriculum in these interrelated disciplines. If competencies were to be developed, they could be tailored to the different roles and responsibilities of the various staff involved.Proposal: We describe a simple theoretical model of functional and behavioural competencies that is based on an organisation with three levels of staff: evidence collectors and gatherers, evidence processors and distillers, and decision makers.Conclusions: To stimulate discussion about how to enhance the progress already being made in pharmacovigilance and patient risk management, we have proposed functional and behavioural competencies for pharmacovigilance as a way of identifying and measuring scientific and personal skills pertinent to pharmacovigilance. Competencies should, we believe, be agreed and adopted by all those seeking to improve pharmacovigilance. We invite discussion of these proposals. Copyright © 2005 John Wiley & Sons, Ltd.
- 1 April 2004
- Published by Annual Reviews in Annual Review of Public Health
- Vol. 25 (1) , 341-356
The Public Health Workforce
The development of a fully-competent public health workforce as a key component of the nation's public health infrastructure has become the focus of increasing attention. The subject is included in one, and is the major topic of a second, report from the Institute of Medicine published late in 2002. Workforce issues have stimulated the convening of the majority of public health–related associations in a range of collaborations on the subjects of defining, enumerating, credentialing, educating, and studying the workforce. The authors review the major questions confronting the field and introduce key components of current thinking about approaches to improvement.
- 1 April 2004
- Published by Annual Reviews in Annual Review of Public Health
- Vol. 25 (1) , 341-356
The Public Health Workforce
The development of a fully-competent public health workforce as a key component of the nation's public health infrastructure has become the focus of increasing attention. The subject is included in one, and is the major topic of a second, report from the Institute of Medicine published late in 2002. Workforce issues have stimulated the convening of the majority of public health–related associations in a range of collaborations on the subjects of defining, enumerating, credentialing, educating, and studying the workforce. The authors review the major questions confronting the field and introduce key components of current thinking about approaches to improvement.